Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 5Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Myelodysplastic-Myeloproliferative Diseases 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Neurofibrosarcoma 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Biphenotypic, Acute 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1Accelerated Phase Myeloproliferative Neoplasm 1

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Allogeneic Stem Cell Transplantation × decitabine and cedazuridine drug combination × Clear all
NCT06297629 2026-05-15

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Withdrawn

Allogeneic Stem Cell Transplantation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡